Viridian Therapeutics opened lower at $31.22, compared with its previous close of $31.25. In the last trading session, the stock traded between $30.31 and $31.30. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Viridian Therapeutics is now worth
$ 165.37
Giving a profit of
$ 65.37 (65.37%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.77 (-2.47%)
Day High
$31.30
Day Low
$30.31
Day Open
$31.22
Prev Close
$31.25
Volume
15,91,182
1W Return
4.96%
1M Return
66.58%
3M Return
32.59%
6M Return
77.20%
1Y Return
7.20%
Fundamentals
Market Cap ($ Mn)
3,461
PE Ratio
-
PB Ratio
4.64
PEG Ratio
-
ROE
-80.47%
ROCE
-56.92%
EPS (TTM)
$-0.81
Investment Returns
1 Week
4.96%
1 Month
66.58%
3 Months
32.59%
6 Months
77.20%
9 Months
1.36%
Financials
Quarterly
All values in $ Mn
0.1
Jun 25
70.6
Sep 25
0.1
Dec 25
0.1
Mar 26
0.3
Jun 26
25.8
Sep 26
Updates
10Nov
Wells Fargo raises Viridian Therapeutics price target to $39
Wells Fargo maintains Overweight rating on Viridian Therapeutics. Price target raised from $34 to $39. Analyst Derek Archila authored the updated report.
2 days ago
9Nov
Viridian VRDN-008 shows 74% IgG reduction; stock up 4.7%
VRDN-008 demonstrated a 74% IgG reduction at peak, sustained through eight weeks. Extended half-life of 15-18 days is up to six times longer than first-generation Fc fragments. Registrational trial for myasthenia gravis planned for mid-2027 using enFuse wearable device. Viridian Therapeutics shares rose 4.69% to $29.83 following the announcement.
3 days ago
6Nov
Leerink Partners raises Viridian Therapeutics price target to $54
Leerink Partners maintains Outperform rating on Viridian Therapeutics. Price target raised from $50 to $54. Analyst Thomas Smith authored the rating update.
7 days ago
5Nov
Wedbush raises Viridian Therapeutics price target to $42
Wedbush analyst Laura Chico raised Viridian Therapeutics' price target from $41 to $42. HC Wainwright previously increased its target from $22 to $40, maintaining a Buy rating. Needham holds a Buy rating with a price target of $38. Three major firms now show converging bullish valuations between $38 and $42.
7 days ago
21Oct
Viridian Therapeutics to report Q3FY26 results on November 4
Viridian Therapeutics will report Q3FY26 financial results on November 4, 2026. Conference call scheduled for 8:00 am ET to discuss results and business updates. Company focuses on autoimmune and rare diseases, including thyroid eye disease treatments.
23 days ago
7Aug
Truist Securities raises Viridian Therapeutics price target to $39
Truist Securities analyst Gregory Renza maintains a Buy rating on Viridian Therapeutics (NASDAQ: VRDN). The firm raised the price target from $38 to $39, signaling sustained confidence in the biotech firm’s valuation.
